Foundation medicine, inc. (FMI)
CashFlow / TTM
Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net loss

-

-152,428

-

-

-

-142,338

-113,192

-96,603

-85,917

-89,973

-89,631

-83,908

-76,292

-57,021

-52,222

-52,016

-51,499

-47,907

-42,944

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

20,391

19,416

18,517

17,928

17,554

17,346

15,949

14,605

13,267

11,463

10,600

9,597

8,761

8,486

8,195

0

0

0

-

-

-

-

Stock-based compensation expense

16,370

19,011

22,202

24,058

24,979

22,884

19,524

16,653

15,057

12,527

11,176

10,563

7,922

6,981

5,989

0

0

0

-

-

-

-

Amortization of premiums and discounts on marketable securities

-

-

-17

-50

-118

-184

-248

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain on disposal of long-lived assets

-

-

327

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,380

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

14

34

46

58

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

10,041

9,095

11,721

6,392

3,227

-2,343

844

-3,170

431

-2,301

-2,361

4,231

4,090

2,712

3,632

1,574

1,954

4,834

4,067

0

0

0

Receivable from Roche

7,292

4,230

8,152

-4,614

2,053

2,502

1,604

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

16,910

5,984

2,576

-1,707

-1,377

3,517

2,446

2,394

3,913

2,250

3,183

5,371

3,654

1,520

3,046

3,252

1,868

2,177

960

0

0

0

Prepaid expenses and other current assets

-145

6,938

3,825

1,569

1,188

154

-1,305

-3,147

-1,846

1,825

3,652

4,653

4,527

2,007

1,873

517

144

303

442

0

0

0

Other assets

550

-236

-210

-550

-325

-269

-210

-181

-225

169

267

651

564

365

282

321

298

95

102

0

0

0

Accounts payable

7,635

11,612

8,434

5,242

4,693

2,756

5,060

-278

4,690

2,014

-1,559

5,981

3,744

5,407

3,119

2,549

-805

-1,379

1,672

0

0

0

Accrued expenses and other current liabilities

2,527

2,855

15,463

6,936

10,780

5,475

8,919

7,181

5,266

2,450

4,704

4,883

4,103

3,699

1,724

2,484

830

3,756

1,515

0

0

0

Deferred rent and other non-current liabilities

-1,238

-2,053

-1,848

522

823

1,696

1,688

1,829

1,443

-922

-1,805

-2,408

-2,231

-60

133

0

0

0

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred revenue

8,637

726

107

-455

742

187

1,387

1,701

1,057

1,614

377

-817

-995

-1,216

-578

-58

-1,194

-1,028

-860

0

0

0

Roche related-party deferred revenue

-4,370

-4,429

5

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-118,239

-

-

-

-98,838

-67,167

-60,845

-44,359

-62,782

-63,726

-65,933

-67,242

-40,212

-42,736

0

0

0

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Investing activities
Purchases of property and equipment

21,950

17,477

15,658

16,843

15,588

17,176

20,879

20,526

28,033

30,692

25,430

20,839

16,112

11,818

9,688

10,899

8,601

6,934

6,930

0

0

0

Purchases of marketable securities and other investments

-

-

4,996

35,007

35,007

80,643

107,456

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

-

-

84,390

124,960

127,960

157,913

141,023

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Financing activities
Change in restricted cash

-

-

-

-

-

-

-

-

-

-

531

0

0

0

-

-

-

-

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash (used in) provided by investing activities

-

31,613

-

-

-

60,094

12,688

-112,274

-157,781

-159,251

-140,717

-20,509

-15,782

-11,994

-8,827

0

0

0

-

-

-

-

Proceeds from indebtedness to Roche

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock option exercises

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuance of restricted stock and stock option exercises

-

-

-

-

-

-

-

-

-

-

4,739

4,745

4,624

4,437

637

368

282

123

49

0

0

0

Proceeds from issuance of common stock from initial public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payments of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,287

1,538

1,713

1,740

1,705

0

0

0

Net cash provided by financing activities

-

97,808

-

-

-

1,761

333

804

826

246,391

250,126

249,943

249,566

3,598

-650

0

0

0

-

-

-

-

Net decrease in cash, cash equivalents, and restricted cash

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

24,358

45,683

163,501

166,542

-48,608

-52,213

-51,266

61,089

64,476

69,455

0

0

0

Cash paid for interest

-

1,361

-

-

-

0

-

-

-

-

-

-

-

-

263

180

191

135

171

0

0

0

Acquisition of property and equipment included in accounts payable and accrued expenses

14,541

7,930

4,098

-180

1,335

628

2,029

6,169

2,297

3,567

6,822

5,727

7,173

4,772

1,334

3,610

4,443

4,875

3,916

0

0

0

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

139

0

0

0